A synthetic biology approach for consistent production of plant-made recombinant polyclonal antibodies against snake venom toxins

Jose Manuel Julve Parreño1, Estefanía Huet1, Asun Fernández-del-Carmen1, Alvaro Segura2, Micol Venturi1, Antoni Gandia1, Wei-song Pan1, Irene Albaldiego1, Javier Forment1, Davinia Pla3, Andrés Wigdorovitz2, Juan J. Calvete3, Carlos Gutiérrez5, José María Gutiérrez2, Antonio Granell1,* and Diego Orzáez1,**

1Instituto de Biología Molecular y Celular de Plantas (IBMC), Agencia Estatal Consejo Superior de Investigaciones Científicas, Universidad Politécnica de Valencia, Valencia, Spain
2Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica
3Instituto de Biomedicina de Valencia, Agencia Estatal Consejo Superior de Investigaciones Científicas, Valencia, Spain
4Instituto de Virología, CICVYa, INTA, Hurlingham Buenos Aires, Argentina
5Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Arucas, Las Palmas, Canary Islands, Spain

Received 30 May 2017; revised 3 August 2017; accepted 23 August 2017.
*Correspondence (Tel +34 963879933; fax +34 963877873; email agranal@ibmcp.upv.es (AG) and dorzaez@ibmcp.upv.es (DO)).

Abstract

Antivenoms developed from the plasma of hyperimmunized animals are the only effective treatment available against snakebite envenomation but shortage of supply contributes to the high morbidity and mortality toll of this tropical disease. We describe a synthetic biology approach to affordable and cost-effective antivenom production based on plant-made recombinant polyclonal antibodies (termed pluribodies). The strategy takes advantage of virus superinfection exclusion to induce the formation of somatic expression mosaics in agroinfiltrated plants, which enables the expression of complex antibody repertoires in a highly reproducible manner. Pluribodies developed using toxin-binding genetic information captured from peripheral blood lymphocytes of hyperimmunized camels recapitulated the overall binding activity of the immune response. Furthermore, an improved plant-made antivenom (plantivenom) was formulated using an in vitro selected pluribody against Bothrops asper snake venom toxins and has been shown to neutralize a wide range of toxin activities and provide protection against lethal venom doses in mice.

Keywords: recombinant polyclonal antibodies, molecular pharming, snake antivenoms.

Introduction

Passive immunization (PI) with polyclonal antibodies (pAbs) purified from animal serum was first adopted to treat diphtheria in the 19th century (Graham and Ambrosino, 2015). Antibiotics and monoclonal antibodies have progressively substituted antisera-based therapies. However, pAbs-based antivenoms remain the only available treatment against complex toxin mixtures such as those present in snake venoms. The global venom burden has been estimated at 2.5 million envenomings and 125 000 deaths per year (Chippaux, 1998). Despite steady improvements (Gutierrez, 2014b; Gutierrez et al., 2011), antivenom-based snakebite treatments are not free of side effects as a consequence of the exposure to heterologous antibody constant regions. Furthermore, antivenom supply is at constant risk due to high manufacturing costs and the low income level of target populations (Arnold, 2016; Harrison et al., 2009). Antivenoms made of recombinant human or humanized antibody cocktails would be a highly desirable alternative as they would reduce the adverse effects while facilitating product standardization and reproducibility. Unfortunately, manufacturing costs for complex antibody cocktails are still high because to ensure consistency they often require parallel production lines for each component of the cocktail. Conversely, simplifying the cocktail composition may compromise its efficacy due to the high diversity of toxins comprising venoms. Furthermore, it is difficult to reconcile moves towards cocktail simplification with a major trend in antivenom formulation, namely to widen the spectrum of snake venoms covered by a single treatment (Lavonas, 2012; Stock et al., 2007).

To overcome these limitations, we have developed a synthetic biology strategy for antivenom production based on the expression of recombinant pAbs in plants. Plant biofactories provide affordable alternative platforms for recombinant antibody production (usually known as ‘plantibodies’) (Stoger et al., 2002) due to their scalability, high production yields, the low risk of contamination with adventitious pathogens and lower requirements for production facility building (Paul and Ma, 2011; Paul et al., 2015). Our proposed strategy uses the plant chassis as a production platform and takes advantage of an intrinsic property of many plant viruses known as superinfection exclusion (SE) to ensure reproducibility. SE prevents the superinfection of cells by a second virus when they are already infected with a closely related resident virus (Julve et al., 2013; Soller and Epstein, 1965; Syller, 2012). An important consequence of SE is the fact that population variants in plant virus infections are not uniformly distributed but structured in a mosaic-like pattern. Most importantly, this distribution ensures the maintenance and propagation of population diversity as compared to the fitness-driven quasispecies-like distributions typical of unstructured population dynamics (Elena et al., 2011). We have investigated the use of virus-based expression systems for the induction of somatic expression mosaics in plant leaves, where each ‘tile’ in the mosaic
functions as an independent monoclonal micro-production line, together leading to the production of recombinant polyclonal cocktails. In this study, we show how this strategy ensures the simultaneous production of high yields of recombinant pAbs comprising hundreds of idiotypes with outstanding batch-to-batch reproducibility, independently of the complexity of the polyclonal composition. Most importantly, we show that this novel strategy enables the expression of a selected portion of a mammalian immunized antibody repertoire in a transiently multitransgenic plant in a highly reproducible manner. We also show that this strategy can be used to synthesize a complex plant-made antibody cocktail able to neutralize a wide range of toxins in the Bothrops asper venom – medically the most important snake in Central America (Gutierrez, 2014a) – thus opening the door to the formulation of efficient and affordable plant-made recombinant antivenoms.

Results
Characterization of somatic expression mosaics in Nicotiana benthamiana

The spatio-temporal dynamics of the mosaic-like expression patterns were monitored in Nicotiana benthamiana leaves after agroinfiltration of three virus-based infective clones encoding GFP, BFP and DsRed fluorescent proteins (Figure 1a). To better understand the dynamics of mosaic formation, we created a 2D computer simulation in NetLogo (see Figure 1b and supporting information) and compared the predicted computer outputs with the experimental mosaic patterns obtained by the simultaneous agroinfiltration of three viral clones encoding fluorescent proteins. Based on the computer simulations, we anticipated that, for a given set of initial parameters, mosaic (colour) composition would be a highly reproducible outcome (Figure 1c) and that reproducibility would increase with the number of initial infection foci. Time-course co-infiltration analysis experimentally corroborated this prediction (Figure 1d). From these observations, we hypothesized that the mosaic distribution pattern of viral clones imposed by SE offers a competition-limited microenvironment that ensures the survival of low-fitness clones. Moreover, with a sufficiently high initial number of infectious foci, SE will also protect the systems from fluctuations in population dynamics, providing highly reproducible outcomes.

Testing expression mosaics for the production of recombinant pAbs: Pluribody technology

In a case study of a multiprotein plant biofactory, we attempted to determine whether this platform could produce high yields of recombinant antibody mixes while preserving the diversity of the composition, ensuring high batch-to-batch reproducibility and yielding a final product that was functionally equivalent to traditional animal antivenom. To assess diversity preservation, we first assayed the in planta expression of an antibody library obtained from camel peripheral mononuclear blood cells (PMBC), comprising a fraction of the antibody repertoire present in the

Figure 1 Principles of superinfection exclusion. (a) N. benthamiana leaves showing somatic expression mosaics produced by three magnICON viral clones encoding DsRed, green and blue fluorescent proteins agroinfected simultaneously at OD600 = 0.01. Mosaics are observed either with red/green filters for DsRed (left) or with UV light (right). Below, detail of the mosaic in the framed leaf area. (b) NetLogo computer simulation of a triple viral co-infection (red, green and blue) subjected to SE in a virtual area comprising 62 500 virtual cells. The virtual fitness (VF) for each clone was adjusted to 1.0 : 1.0 : 0.7 (R:G:B), and virtual OD600 (VOD) was adjusted to 300 (upper image) and 3000 (lower image) arbitrary units to match the natural infection on (a, d) (see Methods for detailed definitions of VF and VOD). (c) Repeated NetLogo simulations of the evolution of triple R-G-B infections using VOD values of 300 (up) and 3000 (down), respectively. (d) Experimental data evolution of triple R-G-B infections in N. benthamiana leaves were performed at two different OD600 and recorded daily up to day 7 postinfiltration. Evolution of clone expansion is represented as percentage of total leaf area occupied by each clone ± SD.
circulating B cells of an individual dromedary camel. Camel antibodies were preferred because camels display large immune repertoires in single chain antibody format (Hcab), a feature that greatly simplifies library construction and subsequent production in plants using viral vectors. Hcab variable antibody regions were PCR-amplified from PMBC cDNA and cloned en masse into the pGVVH-His vector – a modified version of tobacco-mosaic virus (TMV)-derived binary magnICON vector containing an in-frame histidine tag for detection (Figure 2a). The pGVVH-His library was then mobilized to Agrobacterium tumefaciens tumefaciens cells and from here to N. benthamiana leaves using vacuum agroinfiltration. After 7 days’ incubation, leaf apoplast fluid was recovered from detached leaves and the VHH-His were purified by affinity chromatography, resulting in a purified protein band of the expected average size (15 kDa, Figure 2b). As anticipated, a two-dimensional electrophoretic separation resolved the underlying protein complexity and revealed a pattern of >200 distinguishable spots, indicative of the polyclonal nature of the sample (Figure 2c). The resulting plant-made multiple recombinant antibody products are hereafter referred to as pluribody samples. To estimate the size of the repertoires that can be expressed using this system, a GFP clone was co-infiltrated together with the pGVVH-His library at different ratios. It was calculated that one gram of fresh N. benthamiana leaves can produce up to 13 500 expression tiles using an Agrobacterium library inoculum at OD600 = 0.1 (Figure 2c).

Pluribody technology ensures batch-to-batch reproducibility

We then investigated the ability of the system to reproduce the composition and reactivity of mammalian immune subrepertoires. To this end, new antibody libraries in pGVVH-His were constructed starting from PBMC samples obtained from three dromedary camels immunized with the same venom cocktail derived from three snake species, Crotalus simus, Crotalus scutulatus and Bothrops asper. To favour reproducibility and ensure the preservation of the original diversity in any subsequent analysis, the library construction procedure was standardized as shown in Fig. S1 (detailed in Supplementary methods). Working cell bank (WCB) aliquots were first used to evaluate the production strategy in terms of reproducibility, by comparing different VHH-His pluribody preparations. First, three pluribody samples derived from the same immune repertoire but prepared from different WCBs (PIM_1, PIM_2 and PIM_3) were labelled with different fluorophores and resolved by 2D-DIGE analysis. The almost perfect overlapping of DIGE images indicated that all three complex protein samples were remarkably similar (Figure 3a). In a separate DIGE experiment, two immune pluribodies (PIM_1 and PIM_2) were compared with a third preparation derived from a nonimmune repertoire (PPI_1). As the corresponding similarity plots show (Figure 3b), the comparison of the protein spots from equivalent immune pluribody samples (PIM_1 vs PIM_2) produced a narrowly centred volume ratio distribution indicative of a highly reproducible composition. In contrast, comparisons between samples derived from different immune repertoires (PPI_1 vs PIM_1; PPI_1 vs PIM_2) showed clear deviations in volume ratios. Furthermore, deep sequencing of the CDR3 regions in VHH mRNAs from agroinfiltrated plants showed the remarkable conservation of sequence distribution between equivalent samples (PPI1 vs PPI2 and PIM1 vs PIM2), with only very minor differences observed in the most abundant CDR3 sequences (Figure 3c). Finally, when the venom-binding activities of PPI and PIM samples were compared, the immune pluribodies consistently showed reactivity against all three venoms employed for

Figure 2  Assessment of antiserum diversity.
(a) Schema of the cloning and transient expression procedures used for the production of polyclonal VHH antibodies. (b) First and second dimension electrophoretic separation of VHH clones purified from N. benthamiana leaves using NiNTA affinity columns. (c) Expression of a GFP clone as a viral subpopulation within a VHH library. Images were taken after 10 dpi, and the average tile size was recorded and used to estimate tile density and its dependence with OD600 (right). AttB, site-specific recombination site; SP, signal peptide; NTR, nontranslated region; Tnos, terminator of nopaline synthase.
Figure 3 Assessment of pluribody reproducibility. (a) Individual and merged 2D DIGE images of three independent hyperimmune pluribody preparations in V_{H}-His format (PIM_1, PIM_2 and PIM_3). (b) Comparison of the relative abundance of individual antibody clones in plant samples agroinfiltrated with inocula from independent WCBs derived from the same MCB. Antibody clones were identified by deep sequencing of V_{H} CDR3 region. PPI_1 and PP_2 correspond to equivalent pre-immune WCBs. PIM_1 and PIM_2 correspond to equivalent immune polyclonal WCBs. In each comparison, the same colours correspond to identical antibody clones. (c). DIGE comparison of PPI and PIM purified pluribody preparations. Centred dots represent volume ratios close to one. (d) ELISA test showing the venom-binding activity of three nonequivalent PIM preparations each obtained from a different individual camel and analysed against each of the three venoms employed in the immunization. (e) Specificity test of PIM venom binding, comparing reactivity against Crotalus simus and cobra venoms.
immunizations (Figure 3d), and no binding activity was observed against BSA or nonrelated Naja venoms (Naja nubiae and Naja mossambica) (Figure 3e).

**Formulation of a snake plantivenom using Pluribody technology**

In contrast to traditional antivenoms obtained from hyperimmune animal plasma, our pluribodies derive from PMBC pools. Hence, the genetic information retrieved only corresponds to a minor fraction of the reactive B cells made up of circulating memory cells on their way to the bone marrow. Therefore, in order to create a functional plant-made antivenom (hereafter termed plantivenom), we decided to enrich our pluribody repertoires in toxin binders by introducing an intermediate in vitro selection step into the production flow chart (see Fig. S1). PCR-amplified immune subrepertoires were first cloned in a phage display vector and then subjected to three successive rounds of selection against B. asper venom. To maximize diversity and avoid dominant single-antigen selection bias, phage panning was conducted against different fractions of the venom (four in total, roughly corresponding to groups of toxin activities, Figure 4a). After selection, all four sublibraries were pooled and the variable antibody regions were amplified and transferred in bulk to the pGVH-IgG1 vector (Figure 4b) carrying the constant regions of human IgG1 to create an enriched polyclonal (EP) master cell bank (MCB) with increased reactivity and potentially less likely to produce hypersensitivity reactions. EP_MCB was subsequently distributed in WCBs and agroinfiltrated in N. benthamiana. The PEP_1 formulation showed a 2xlog increase in total binding activity when compared with the nonenriched pluribody in ELISA (Figure 5A), demonstrating that enrichments in polyclonal compositions obtained by in vitro selection can be successfully transferred to the plant, where they globally reproduce the reactivity gains.

Finally, in order to produce the first iteration for a plantivenom candidate, we decided to produce a pluribody incorporating 36 individual clones that showed maximum binding activities. The clone composition of the resulting enriched oligoclonal formulation (EO_1, see Fig. S1) is detailed as supplementary information (Table S1). An EO_WCB was employed to scale up antibody production using one kilogram of agroinfiltrated N. benthamiana leaves and yielding 0.2 g of recombinant polyclonal antibody collected from the corresponding leaf apoplastic fluid. Following affinity purification (Figure 5A), an antivenom solution in PBS (PEO_1) was prepared at a concentration of 46.5 mg protein/mL, similar to the typical concentration of equivalent commercial antivenoms (55 mg/mL), and used for further characterization (summarized in Table 1). As expected, the PEO_1 solution showed enriched antivenom-binding activity when assayed in ELISA against B. asper venom (Figure 5B, C). Figure 5D showed that phospholipases (PLA2), and to a lesser extent serine proteinases (SP), P-I and P-III snake venom metalloproteinases (SVMP) and L-amino acid oxidase (LAO) molecules, were efficiently retained by the immobilized plantivenom. However, the affinity matrix was poor in capturing disintegrins (DISI). Such pattern of immunorecognition mirrors the immunological profile of monospecific (B. asper) antivenoms (Gutierrez et al., 2010), which were shown to quantitatively immunocapture most P-III SVMPs, serine proteinases, L-amino acid oxidase, but only to a lesser extent medium-sized disintegrins, PLA2 molecules, some

![Figure 4](image-url)  
**Figure 4** Strategy for pluribody formulation enrichment. (a) Chromatographic profile and electrophoresis separation of Bothrops asper venom employed in antivenom pluribody enrichment, showing the four groups of toxins employed in phage display selection to reduce antigen drift. (b) Cloning procedure for VHH variable regions from PBMC cDNA to pHEN2-derived pSword phage display vector and from here to binary vector for plant expression adapted from magnICON deconstructed system.
serine proteinases and P-I SVMP BaP1. Later, the ability of PEO_1 to neutralize different B. asper toxic and enzymatic activities was analysed. The PEO_1 plantivenom was able to neutralize venom haemorrhagic, PLA2, proteinase and lethal activities (Table 1). Figure 5C illustrates the neutralization of haemorrhagic activity in the mouse skin test. The plantivenom did not neutralize in vitro coagulant activity on plasma at the maximum concentration tested (372 mg plantivenom/mg venom) (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose’. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (Table 1). Finally, we tested the capacity of PEO_1 to neutralize lethality induced by B. asper venom in mice, using 2 LD₅₀ doses of venom as ‘challenge dose'. PEO_1 prevented lethality in all injected mice at a ratio of 61.24 mg plantivenom/mg venom (supporting information) with an estimated median effective dose (ED₅₀) of 43 mg plantivenom/mg venom (95% confidence limits: 33–56 mg/mg) (Table 1). All PEO_1 neutralization activities were assayed in parallel with a commercial horse-derived antivenom, and the corresponding neutralizing activities are also summarized in Table 1. Horse-derived antivenom was effective in the neutralization of all enzymatic and toxic effects assayed.

Discussion

Global antivenom shortage has prompted several lines of research aimed at finding solutions to the main production bottlenecks. The use of immunization with DNA or with recombinant-expressed epitopes of relevant toxins is an example of this, aimed at circumventing the shortage of antigens in species with low venom yield, such as coral snakes (Ramos et al., 2016). In comparison, fully recombinant strategies can provide a more satisfactory solution in the long term, addressing not only the shortage of antigens, but also other problems arising from current therapies such as adverse reactions and reproducibility (Laustsen et al., 2016). In theory, rationally designed cocktail formulations made of recombinant mAbs could outperform animal plasma-derived antivenoms, as the composition of the latter comprises a large fraction (≥80%) of immunologically irrelevant antitoxin antibodies. In contrast, by adjusting the antivenom composition to a minimal number of selected functional components, the safety profile can be improved and manufacturing costs can be reduced. Minimal recombinant antibody cocktails comprising only three mAbs antibodies against the main Bothrops toxins were shown to neutralize the lethal toxicity of the venom (Frauches et al., 2013), indicating that oligoclonal cocktails are suitable antivenom formulations at least in some cases. Notwithstanding, a potent cocktail would probably require more complex combinations, incorporating antibodies against minor toxins, which could act alone or synergistically with other toxins, to ensure the coverage of intra- and interspecific venom components.
Neutralization of haemorrhagic, phospholipase A₂, proteolytic and lethal activities of Bothrops asper venom is expressed as median effective dose (ED₅₀), whereas neutralization of coagulant activity is expressed as effective dose (ED₅₀), in terms of mg plantivenom or antivenom/mg venom protein (see Materials and methods for details). Results are presented as mean ± SD (n = 3) for neutralization of haemorrhagic, phospholipase A₂, proteinase and coagulant effects. In the case of neutralization of lethal effect, the 95% confidence limits are included in parenthesis.

| Toxic and enzymatic activities of B. asper venom | ED₅₀ Plantivenom (mg/mg venom) | ED₅₀ Equine-derived (mg/mg venom) |
|------------------------------------------------|-------------------------------|---------------------------------|
| Haemorrhagic                                     | 22.2 ± 0.65                   | 6.9 ± 0.01                      |
| Phospholipase A₂                                 | 224.1 ± 13.2                  | 37.4 ± 0.4                      |
| Proteolytic                                      | 120.5 ± 4.2                   | 43.0 ± 2.0                      |
| Peritoneal lethality                             | 43.2 (33.4–56.0)              | 3.1 (1.2–8.4)                   |
| Coagulant on                                     | ≥372                         | 11.3 ± 0.13                     |
| human plasma                                     |                               |                                 |

Neutralization of haemorrhagic, phospholipase A₂, proteinase and lethal activities is expressed as median effective dose (ED₅₀), whereas neutralization of in vitro coagulant activity is expressed as effective dose (ED₅₀), in terms of mg plantivenom or antivenom/mg venom protein (see Materials and methods for details). Results are presented as mean ± SD (n = 3) for neutralization of haemorrhagic, phospholipase A₂, proteinase and coagulant effects. In the case of neutralization of lethal effect, the 95% confidence limits are included in parenthesis.

The PEO₁ cocktail described here showed a reasonable spectrum of neutralizing activities with relatively little effort in antibody selection; however, further efforts will be required to reach efficacy levels of current commercial antivenoms. Envenomings by Bothrops asper are characterized by several pathological and pathophysiological alterations, among which alterations in the coagulation are important. Thus, any antivenom to be considered for use in envenomings by B. asper should be able to neutralize the coagulant effect of the venom. This should prompt further efforts to increase the neutralizing capacity of the plantivenom and to generate neutralization of the coagulant effect. With consistency and reproducibility ensured with the pluribody strategy, the opportunities for formulation improvements through the implementation of successive design–build–test cycles are manifold. The neutralization of coagulant activity can be improved with the introduction of new serine protease neutralizing clones from improved antibody selection procedures, synthetic repertoires or alternative single-cell selection methods (Beerli and Rader, 2010). A streamlined formulation should also involve the elimination of clones with overlapping or non-neutralizing activities and, ultimately, the incorporation of neutralizing activities against other snake venoms from the same region. Our results should be followed by a more in depth preclinical assessment of the plantivenom, using various animal and in vitro models. Once a plantivenom with the capacity to neutralize all toxic activities of the venom is developed, the next step would be to consider the implementation of clinical trials and to establish clinical doses. The dose of antivenom to be administered in clinical cases cannot be directly extrapolated from the preclinical neutralization tests. It has been roughly estimated that an adult B. asper specimen may inject 50 mg of venom in a bite, although this varies from bite to bite according to many variables (size of the snake, volume of venom available in the gland, strength of the bite, etc.). Once an antivenom has demonstrated efficacy in preclinical tests, clinical trials involve an initial dose-finding phase, in which the optimal dose of antivenom is selected. This dose is then used for more extensive clinical trials with a higher number of patients.

The manipulation of SE for manufacturing purposes is pivotal in the pluribody approach. SE ensures the independence of each cell selection methods (Beerli and Rader, 2010). A streamlined formulation should also involve the elimination of clones with overlapping or non-neutralizing activities and, ultimately, the incorporation of neutralizing activities against other snake venoms from the same region. Our results should be followed by a more in depth preclinical assessment of the plantivenom, using various animal and in vitro models. Once a plantivenom with the capacity to neutralize all toxic activities of the venom is developed, the next step would be to consider the implementation of clinical trials and to establish clinical doses. The dose of antivenom to be administered in clinical cases cannot be directly extrapolated from the preclinical neutralization tests. It has been roughly estimated that an adult B. asper specimen may inject 50 mg of venom in a bite, although this varies from bite to bite according to many variables (size of the snake, volume of venom available in the gland, strength of the bite, etc.). Once an antivenom has demonstrated efficacy in preclinical tests, clinical trials involve an initial dose-finding phase, in which the optimal dose of antivenom is selected. This dose is then used for more extensive clinical trials with a higher number of patients.

The manipulation of SE for manufacturing purposes is pivotal in the pluribody approach. SE ensures the independence of each micro-production line, resulting in highly reproducible final products. The resulting structured population distribution simplifies the modelling of the production process, as the whole system can be regarded as the sum of thousands of independent micro-production lines (expression tiles) working in parallel. This work also underscores the potential of plant synthetic biology to offer the world new bio-fabrication solutions. Pluribody technology combines genetic elements from biological sources as distant as camels, humans and plant viruses to capture the immune repertoire of hyperimmunized camels and recapitulate this within the plant chassis, creating plantivenoms able to neutralize a wide range of toxin activities that provide protection against lethal venom doses in mice. Beyond antivenoms, we believe that the ability to formulate pluribodies à la carte could provide a new boost to passive immunotherapy, facilitating the formulation and manufacturing of new, affordable antitoxin and antimicrobial products.
Materials and methods

Detailed information about the experimental methods can be found in SI. All procedures involving experimental mice meet the requirements of the Guiding Principles for Biomedical Research Involving Animals (CIOMS, 1985) and were approved by the Institutional Committee for the Care and Use of Laboratory Animals of Universidad de Costa Rica (approval number 82-08). The camel immunization protocol followed animal experimentation guidelines published by the regional government of the Canary Islands (Spain) and was approved by the Ethics Committee, Veterinary Medicine Service, Las Palmas de Gran Canaria University Foundation (Ref.: 009/2011)

Snake venoms and venom fractions

Venoms were obtained from specimens of B. asper, C. scutulatus, C. simus and C. dromedarius from the Serpentarium of the Instituto Clodomiro Picado (University of Costa Rica, San José). For venom fractionation, B. asper venom proteins were separated by reverse-phase HPLC; the resolved chromatographic peaks (48) were collected separately and the eluted fractions pooled in four groups: group 1 was mainly composed of disintegrins; group 2 of phospholipases; group 3 mainly contained serine proteases and PLA2; and group 4 was enriched in metalloproteinases.

Camel immunization, total RNA isolation and amplification of VHH sequences

Three camels (Camelus dromedarius) were immunized with a cocktail containing equal amount of each of three snake venoms (C. scutulatus, C. simus and B. asper). Peripheral blood lymphocytes (PBLs) obtained from ‘pre-immune’ and ‘immune’ samples were used to isolate RNA and synthesize cDNA to be used as template for PCR amplification of VHH coding sequences (see supplementary materials and methods and Table S2 for the list of primers used).

VHH Phage Display library construction and selection

The amplified VHH sequences were directly cloned as PCR products into the pSword phagemid vector and the ligation products transformed into E. coli. In a first round, venom binders were selected using B. asper full venom as the antigen. Subsequent selection rounds were carried out separately against each one of the four antigen groups obtained by venom fractionation. Monitoring of the library enrichment was carried out by polyclonal phage ELISA on B. asper full venom. Monoclonal phage ELISA was carried out in the same way from individual clones of the third round of selection; clones showing the highest binding affinity for each individual antigen were selected to formulate an oligoclonal mix: two clones from group 1; eight from group 2; six from group 3; and 20 from group 4 (SI).

VHH plant expression libraries

VHH sequences amplified from PBL cDNA were directly cloned as PCR products into pGVHH-His. Selected VHH phage display libraries and individual clones were cloned in pGVHH-H-IgG vector. pGVHH-H-His and pGVHH-H-IgG are adaptation of the magnICON plant viral expression vector pICH7410 (ICON Genetics) built on a pDGB1 vector backbone (Sarrion-Perdigones et al., 2011). Ligation products were transformed into E. coli cells and plated on solid LB agar plates. For libraries, bacteria were scraped and stored in 1 mL aliquots as E. coli library stocks. One-tenth of the library was used for plasmid DNA isolation. For individual clones, a single colony was used to inoculate a fresh culture that was afterwards used for plasmid DNA isolation, the remaining culture being stored in 1 mL aliquots as E. coli glycerol stocks. The isolated plasmid DNA was transformed into the Agrobacterium tumefaciens GV3101 strain. The transformation was spread on LB plates. Bacteria were scraped and stored in 500 μL aliquots as library stocks to create a master cell bank (MCB). MCB aliquots were grown O/N and distributed in working cell banks (WCB) used for agroinfiltration.

Estimation of the polyclonal diversity of the somatic mosaic

To determine average tile size in a typical polyclonal experiment, a pGVHH-H-His antibody library was mixed with a pGGFP clone in different ratios (1%, 5% and 10%) and co-infiltrated at different OD600s (0.1, 0.03, 0.01 and 0.003) in N. benthamiana leaves. Images of each experimental point taken at days 5 and 10 p.i were analysed with ImageJ software (http://rsb.info.nih.gov/ij/), and the number of tiles and average tile size were calculated using the ‘Analyse particle’ function. An experimental surface weight conversion rate of 35.2 cm²/g FW in N. benthamiana leaves was applied to calculate the number of expression tiles per biomass.

Transient expression in Nicotiana benthamiana

For polyclonal and oligoclonal agroinfiltrations, an aliquot of the WCB collection was used to inoculate an appropriate volume of LB supplemented with antibiotics (1 : 250 subculture); cultures were grown for 8 h at 28 °C. Cultures were collected by centrifugation (10 min, 3000 g), re-suspended in agroinfiltration medium (10 mM MES pH 5.6, 10 mM MgCl₂, 200 μM acetoxy-ringone) to an optical density at 600 nm of 0.05 and incubated for 2 h at room temperature on a horizontal rolling mixer. Before infiltration, the bacterial suspensions harbouring VHH-6xHis or VHH-H-Fc (3’-provector modules) were mixed with equal volumes of the pICH14011 (Integrate) and pICH7388 (5’-provector module) suspensions. For agroinfiltration, 5- to 6-week-old N. benthamiana plants were submerged in the agroinfiltration solution, a vacuum was applied to a pressure of –0.9 bar (Vacuum Degassing Chamber DP118, Applied Vacuum Engineering, Thornbury, UK), held for 1 min and then slowly released. Samples for protein extraction were collected 7–10 days postinfiltration.

Analysis of diversity and reproducibility at DNA level

Sequencing libraries were prepared from VHH-6xHis immune and pre-immune library agroinfiltrated N. benthamiana leaves (see supplementary materials and methods and Table S2 for the list of primers used). Libraries were sequenced on an Ion Torrent PGM at Life Sequencing (Valencia, Spain). Sequence quality trimming, de novo assembly and posterior analysis were conducted using custom Python scripts and jAssembler software (Zheng et al., 2011). Unigenes composed of at least two members were used for library comparison by BLASTN using the Blast User DB tool at http://ncbi11.biologie.uni-kl.de/.

Computer simulation of Somatic expression mosaics

Simulation of expression mosaic formation was performed with NetLogo 6.0 agent-based modelling software (Wilensky, 1999), with a script designed to simulate cell-to-cell movement of exclusion-enabled viral clones on two-dimensional hexagonal grid (Wilensky, 2007) (http://pgb.ibmcp.csic.es/netlogo/netlogo.html and SI).
Antivenomics

Affinity chromatography-based antivenomic (Pla et al., 2012) was employed to address the immunocapturing ability of PEO_1 towards B. asper venom components. Columns were prepared by immobilizing plantivenom on cyanoan bromide-activated Sepharose 6 MB (SIGMA, St. Louis, USA), following the manufacturer's instructions. The column was then loaded with B. asper venom pooled from B. asper specimens from the Pacific versant of Costa Rica. Bound and nonretained fractions were analysed by HPLC. Chromatographic runs of whole B. asper venom dissolved in PBS were used as controls.

Neutralization of toxic activities

The ability of plantivenom to neutralize proteinase, phospholipase A2 (PLA2), hemorrhagic, coagulant, and lethal activities was determined as previously described (Bolanos, 1972; Gene et al., 1989; Gutierrez et al., 1985; Gutierrez et al., 1986; Gutierrez et al., 2008, Theakston and Reid, 1983; Wang et al., 2004). Neutralization was expressed as median effective dose (ED50) for lethal, haemorrhagic, proteinase and PLA2 activities (plantivenom/venom, or equine antivenom/venom, ratio in which the effect was inhibited by 50% (Segura et al., 2010)), or as effective dose (ED) for coagulant activity (the plantivenom/venom, or equine antivenom/venom, ratio in which the clotting time was prolonged three times as compared to venom incubated with PBS instead of antibodies (Gene et al., 1989).

Acknowledgments

We thank Brian J. Robinson for his careful revision of the manuscript. The work carried out at IBV-CSCIS received financial support from MINECO and ERDF (project grants IPT-2011-0720-010000, BIO2013-42193-R and BIO2016-78601-R). Research at IBV-CSCIS was supported by grant BFU2013-42833-P from the Spanish Ministry of Economy and Competitiveness, Madrid, Spain. The authors declare no conflict of interest.

References

Arnold, C. (2016) Synthetic biology tackles global antivenom shortage. Nature, 532, 292.
Beeri, R.R. and Rader, C. (2010) Mining human antibody repertoires. MAbs, 2, 365–378.
Bendiard, M., Marillonnet, S., Kandzia, R., Thiene, F., Nickstadt, A., Herz, S., Frode, R. et al. (2010) Rapid, high-yield production in plants of individualized idiotypic vaccines for non-Hodgkin’s lymphoma. Ann. Oncol., 21, 2420–2427.
Bolanos, R. (1972) Toxicity of Costa Rican snake venoms for the white mouse. Am. J. Trop. Med. Hyg. 21, 360–363.
Chippaux, J.P. (1998) Snake-bites: appraisal of the global situation. Bull. World Health Organ. 76, 515–524.
Elena, S.F., Bedhomme, S., Carrasco, P., Cuevas, J.M., de la Iglesia, F., Lafforgue, G., Lalic, J. et al. (2011) The evolutionary genetics of emerging plant RNA viruses. Mol. Plant Microbe Interact. 24, 287–293.
Frauches, T.S., Petretski, J.H., Arnholdt, A.C.V., Lasunskaia, E.B., de Carvalho, E.C.Q., Kipnis, T.L., da Silva, W.D. et al. (2013) Bothropic antivenom based on monoclonal antibodies, is it possible? Toxicon, 71, 49–56.
Gene, J.A., Roy, A., Rojas, G., Gutierrez, J.M. and Cerdas, L. (1989) Comparative study on coagulant, defibrinating, fibrinolytic and fibrinogenolytic activities of Costa Rican crotaline snake venoms and their neutralization by a polyvalent antivenom. Toxicon, 27, 841–848.
Graham, B.S. and Ambrosino, D.M. (2015) History of passive antibody administration for prevention and treatment of infectious diseases. Current Opin. HIV AIDS, 10, 129–134.

Gutierrez, J.M. (2014a) Current challenges for confronting the public health problem of snakebite envenoming in Central America. J. Venom Anim. Toxins Ind. Trop. Dis. 20, 7.
Gutierrez, J.M. (2014b) Reducing the impact of snakebite envenoming in Latin America and the Caribbean: achievements and challenges ahead. Trans. R. Soc. Trop. Med. Hyg. 108, 530–537.
Gutierrez, J.M., Gene, J.A., Rojas, G. and Cerdas, L. (1985) Neutralization of proteolytic and hemorrhagic activities of Costa Rican snake venoms by a polyvalent antivenom. Toxicon, 23, 887–893.
Gutierrez, J.M., Lomonte, B., Chaves, T., Moreno, E. and Cerdas, L. (1986) Pharmacological activities of a toxic phospholipase A isolated from the venom of the snake Bothrops asper. Comp. Biochem. Physiol. C, Comp. Pharmacol. Toxicol. 84, 159–164.
Gutierrez, J.M., Sanz, L., Escolano, J., Fernandez, J., Lomonte, B., Angulo, Y., Rucavado, A. et al. (2008) Snake venomics of the Lesser Antillean pit vipers Bothrops caribaexus and Bothrops lanceolatus: correlation with toxicological activities and immunoreactivity of a heterologous antivenom. J. Proteome Res. 7, 4396–4408.
Gutierrez, J.M., Sanz, L., Flores-Diaz, M., Figueroa, L., Madrigal, M., Herrera, M., Villalba, M. et al. (2010) Impact of regional variation in Bothrops asper snake venom on the design of antivenoms: integrating antivenomics and neutralization approaches. J. Proteome Res. 9, 564–577.
Gutierrez, J.M., Leon, G. and Burnof, T. (2011) Antivenoms for the treatment of snakebite envenomings: the road ahead. Biologics, 39, 129–142.
Harrison, R.A., Hargreaves, A., Wagstaff, S.C., Faragher, B. and Lalloy, D.G. (2009) Snake envenoming: a disease of poverty. PLoS Negl. Trop. Dis. 3, e569.
Julu, J.M., Gandia, A., Fernandez-Del-Carmen, A., Sarrion-Pedrones, A., Casteljins, B., Granell, A. and Orzaez, D. (2013) A coat-independent superinfection exclusion rapidly imposed in Nicotiana benthamiana cells by tobacco mosaic virus is not prevented by depletion of the movement protein. Plant Mol. Biol. 81, 553–564.
Lausten, A.H. (2016) Snakebites: costing recombinant antivenoms. Nature, 538, 41.
Lausten, A.H., Engmark, M., Milbo, C., Johansson, L., Lomonte, B., Gutierrez, J.M. and Lohse, B. (2016) From fangs to pharmacology: the future of snakebite envenoming therapy. Curr. Pharm. Des. 22, 5270–5293.
Lavonas, E.J. (2012) Antivenoms for snakebite: design, function, and controversies. Curr. Pharm. Biotechnol., 13, 1980–1986.
Marillonnet, S., Grittich, A., Gils, M., Kandzia, R., Klimyk, V. and Gleba, Y. (2004) In planta engineering of viral RNA replicons: Efficient assembly by recombination of DNA modules delivered: Agrobacterium. Proc. Natl. Acad. Sci. USA, 101, 6852–6857.
Marillonnet, S., Thoeringer, C., Kandzia, R., Klimyk, V. and Gleba, Y. (2005) Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat. Biotechnol. 23, 718–723.
Paul, M. and Ma, J.K. (2011) Plant-made pharmaceuticals: leading products and production platforms. Biotechnol. Appl. Biochem. 58, 58–67.
Paul, M.J., Thangarat, H. and Ma, J.K. (2015) Commercialization of new biotechnology: a systematic review of 16 commercial case studies in a novel manufacturing sector. Plant Biotechnol. J. 13, 1209–1220.
Pla, D., Gutierrez, J.M. and Calvete, J.J. (2012) Second generation snake antivenomics: comparing immunoadfinity and immunodepletion protocols. Toxicon, 60, 688–699.
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J.B., Fausther-Bovendo, H. et al. (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature, 514, 47–53.
Ramos, H.R., Junqueira-de-Azevedo Ide, L., Novo, J.B., Castro, K., Duarte, C.G., Machado-de-Avila, R.A., Chavez-Olortegui, C. et al. (2016) A heterologous multipeptide DNA prime/recombinant protein boost immunisation strategy for the development of an antisera against micrurus corallinus (Coral Snake) venom. PLoS Negl. Trop. Dis. 10, e0004484.
Rasmussen, S.K., Naested, H., Muller, C., Tolstrup, A.B. and Frandsen, T.P. (2012) Recombinant antibody mixtures: production strategies and cost considerations. Arch. Biochem. Biophys. 526, 139–145.
Sarrion-Pedrones, A., Falconi, E.E., Zandalinas, S.I., Juarez, P., Fernandez-del-Carmen, A. and Granell, A. (2011) GoldenBraid: an iterative cloning system for standardized assembly of reusable genetic modules. PLoS ONE, 6, e21622.

© 2017 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 16, 727–736.
Segura, A., Castillo, M.C., Nunez, V., Yarleque, A., Goncalves, L.R., Villalta, M., Bonilla, C. et al. (2010) Preclinical assessment of the neutralizing capacity of antivenoms produced in six Latin American countries against medically-relevant Bothrops snake venoms. Toxicon, 56, 980–989.

Soller, A. and Epstein, H.T. (1965) Biochemical and immunological aspects of the exclusion of lambda by superinfection with T4. Virology, 26, 715–726.

Stock, R.P., Massougbdji, A., Alagon, A. and Chippaux, J.P. (2007) Bringing antivenoms to Sub-Saharan Africa. Nat. Biotechnol. 25, 173–177.

Stoger, E., Sack, M., Fischer, R. and Christou, P. (2002) Plantibodies: applications, advantages and bottlenecks. Curr. Opin. Biotechnol. 13, 161–166.

Syller, J. (2012) Facilitative and antagonistic interactions between plant viruses in mixed infections. Mol. Plant Pathol. 13, 204–216.

Theakston, R.D. and Reid, H.A. (1983) Development of simple standard assay procedures for the characterization of snake venom. Bull. World Health Organ. 61, 949–956.

Walwyn, D.R., Huddy, S.M. and Rybicki, E.P. (2015) Techno-economic analysis of horseradish peroxidase production using a transient expression system in Nicotiana benthamiana. Appl. Biochem. Biotechnol. 175, 841–854.

Wang, W.J., Shih, C.H. and Huang, T.F. (2004) A novel P-I class metalloproteinase with broad substrate-cleaving activity, agkislysin, from Agkistrodon acutus venom. Biochem. Biophys. Res. Commun. 324, 224–230.

Wilensky, U. (1999) NetLogo. http://ccl.northwestern.edu/netlogo/.

Wilensky, U. (2007) NetLogo Hex Cell Aggregation model. http://ccl.northwestern.edu/netlogo/models/HexCellAggregation.

Zheng, Y., Zhao, L., Gao, J. and Fei, Z. (2011) iAssembler: a package for de novo assembly of Roche-454/Sanger transcriptome sequences. BMC Bioinform. 12, 453.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Figure S1 Schema for the production of different pluribody formulations representing camel antibody subrepertoires.

Table S1 Characterization of individual clones comprising PEO_1 plantivenom. Binding activities against venom and compared with BSA are shown next to the amino acid sequence.

Table S2 Primers used for VHH cloning and generation of sequencing libraries.